ASSESSMENT OF METABOLIC SYNDROME IN PATIENTS WITH CHRONIC URTICARIA

Thesis

Submitted for partial fulfillment of master degree in *Dermatology and Venereology*

Presented by

Howaida Osama Mohamed Farid

(M.B, B. Ch)
Faculty of Medicine - Ain Shams University

Supervised by

Prof. Dr. May Hussein El Samahy

Professor of Dermatology, Venereology and Andrology Faculty of Medicine - Ain Shams University

Dr. Mahmoud Abdel-Rahim Abdallah

Associate Professor of Dermatology, Venereology and Andrology Faculty of Medicine - Ain Shams University

> Faculty of Medicine Ain Shams University 2016



سورة البقرة آية (٣٢)

Acknowledgement

First of all and foremost, Thanks to God. Who is behind every success, the most kind and the most merciful.

It is a pleasure to express my deepest thanks and profound respect to my honored professor, *Prof. Dr. May Hussein El Samahy, Professor and head of Dermatology, Venereology and Andrology Department Faculty of medicine, Ain Shams University* for her continuous encouragement and valuable supervision and guidance throughout this work. I wish to be able one day to return to her a part of what she had offered to me.

Also, I wish to express my deep gratitude and sincere thanks to *Dr. Mahmoud Abdallah*, *Associate Professor of Dermatology, Venereology and Andrology Faculty of medicine, Ain Shams University,* for his kind support, help and careful supervision and his continuous guidance and explanation.

No words could adequately express my deep appreciation to my parents, my husband, my brothers and my sister, for their continuous support and guidance. I shall remain indebted to them all my life. Finally all my love to my little two girls.

Howaida Osama

List of Contents

T	Title Page			
•	Li	st of Abbreviations		
•	Li	st of TablesIV		
•	Li	st of FiguresVI		
•	In	troduction1		
•	Ai	im of the Work5		
•	R	eview of Literature		
	C	hapter (1): Urticaria6		
	_	Definition6		
	-	Epidemiology6		
	-	Types		
	_	Clinical picture14		
	-	Histopathology18		
	_	Pathogenesis		
	_	Diagnosis24		
	-	Treatment30		
	C	hapter (2): Metabolic syndrome44		
	-	Introduction44		
	-	Definition		
	-	Epidemiology45		
	-	Pathogenesis47		
	-	Diagnostic criteria52		
	-	Risk factors55		
	-	Complications63		
	-	Metabolic syndrome and skin diseases65		
	-	Treatment67		

List of Contents (Cont.)

	Title	Page
•	Subjects and Methods	75
•	Results	81
•	Discussion	106
•	Conclusions & Recommendations	118
•	Summary	120
•	References	123
•	Arabic Summary	

List of Abbreviations

AACE	.American Endocrinol		of	Clinical
ACE	.Angiotensir	n converting e	nzym	ıe
ADN	.Adiponectin	ı		
APST	.Autologous	Plasma Skin	Test	
ASST	.Autologous	Serum Skin 7	l'est	
BMI	.Body Mass	Index		
CD	.Cluster of I	Differentiation		
CIU	.Chronic Idi	opathic Urtica	ıria	
CMS	.Cardiac Me	tabolic Syndro	ome	
CNS	.Central Ner	vous System		
COPD	.Chronic Disease	Obstructive	Pu	lmonary
CSU	.Chronic Sp	ontaneous Ur	ticar	ia
CU	.Chronic Ur	ticaria		
CVD	.Cardiovasc	ular Disease		
DBP	.Diastolic B	lood Pressure		
DM2	.Diabetes M	ellitus Type 2		
DPU	.Delayed Pro	essure Urticar	ia	
EAACI	.European <i>E</i> Clinical Im		ergo	logy and
ECP	.Eosinophil	Cationic Prote	ein	
EDF	.European I	Dermatology F	orun	n
EGIR	.European Insulin Res		ne S	Study of
ESR	.Erythrocyte	e Sedimentation	n Ra	ate
FBG	.Fasting Blo	od Glucose		
FceRI	.High-Affini	ty Receptor for	gE	

List of Abbreviations

FFA	.Free Fatty Acids
G6PD	.Glucose-6 Phosphate Dehydrogenase
GA2LEN	.Global Allergy and Asthma European Network
GM-CSF	.Granulocyte Macrophage Colony Stimulating Factor
HDL	.High Density Lipoprotein
HDL-C	.High Density Lipoprotein-Cholesterol
НРА	.Hypothalamic Pituitary Axis
ID	.Intra Dermal
IDF	.International Diabetes Federation
IFG	.Impaired Fasting Glucose
IgG	.Immunoglobulin G
IGT	.Impaired Glucose Tolerance
IR	.Insulin Resistance
IRS	.Insulin Receptor Substrate
LDL	.Low Density Lipoproteins
LTRA	Leukotriene Receptor Antagonists
MBP	.Major Basic Protein
MEP	.Mediterranean Food Pattern
Met S	.Metabolic Syndrome
MMP-9	.Matrix Metalloproteinase -9
Nampt	. Nicotinamide Phosphoribosyl Transferase
NASH	.Nonalcoholic Steatohepatitis
NCEP ATP II	.National Cholesterol Education Program Adult Treatment Program III
NSAID	.Non-Steroidal Anti-Inflammatory Drugs
OGTT	.Oral Glucose Tolerance Test

List of Abbreviations

PAF	Platelet Activating Factor
PAI-1	Plasminogen Activator Inhibitor
PCOS	Polycystic Ovarian Syndrome
PG2	Prostaglandin2
PUVA	Phototherapy with UV Light
S IgE	Serum Immunoglobulin E
SBP	Systolic Blood Pressure
sсн	Subclinical Hypothyroidism
SD	Standard Deviation
SNS	Sensory Nervous System
тс	Total Cholesterol
TG	Triglycerides
TNF	Tumor Necrosis Factor
UVB	Ultraviolet B
UVR	Ultraviolet Rays
VAF	Visceral Abdominal Fat
VLDL	Very Low Density Lipoproteins
VTE	Venous Thromboembolism
WAO	World Allergy Organization
WHO	World Health Organization

List of Tables

Table No.	Title	Page
Table (1.1):	Urticaria Classification	8
Table (1.2):	Recommended diagnostic test	
	irequent articaria sustypes	
Table (2.1):	ATPIII diagnostic criteria for Mo	etS 54
Table (4.1):	Demographic data of the patier	nts 81
Table (4.2):	Demographic data of controls	82
Table (4.3):	Comparison between patients controls regarding demogradata	phic
Table (4.4):	Anthropometric measurement and blood pressure of the patie	
Table (4.5):	Anthropometric measurement and blood pressure of controls.	
Table (4.6):	Comparison between patients controls regarding anthropom measurements and blood press	etric
Table (4.7):	Laboratory findings of the patie	ents 87
Table (4.8):	Laboratory findings of controls	88

List of Tables

Table No.	Title	Page
Table (4.9):	Comparison between patie controls regarding laifindings	boratory
Table (4.10):	Metabolic syndrome paramethe patients	
Table (4.11):	Metabolic syndrome parameters controls	
Table (4.12):	Comparison between patie controls regarding management syndrome parameters	netabolic

List of Tables (Cont.)

Table No.	Title	Page	
Table (4.13):	The prevalence of metabolic syndrome among studied subjects.		
Table (4.14):	Age and Sex among metabolic and non-metabolic urticaria patients		
Table (4.15):	The prevalence of ASST in patients 96		
Table (4.16):	Prevalence of individual metabolic syndrome criteria in patients and controls		
Table (4.17):	Comparison between patient's Subgroups		
Table (4.18):	Metabolic syndrome in chronic urticaria patients with and without angioedema		
Table (4.19):	Relation between chronic urticaria duration and metabolic syndrome		
Table (4.20):	Relation between chronic urticaria duration and metabolic syndrome parameters	:	
Table (4.21):	Relation between chronic urticaria duration and ASST		

List of Figures

Figure No.	Title Page
Fig. (1.1):	Scratched into the skin of someone with dermographism
Fig. (1.2):	Immunologicalandnon-immunologicalactivationofmastcells21
Fig. (1.3):	EAACI / GA ² LEN / EDF / WAO Guidelines
Fig. (2.1):	Pathogenesis of Metabolic Syndrome 51
Fig. (4.1):	The prevalence of metabolic syndrome among studied subjects 93
Fig. (4.2):	Age and Sex among metabolic and non-metabolic urticaria patients 95
Fig. (4.3):	ASST in our studied patients97
Fig. (4.4):	The prevalence of ASST in patients 98
Fig. (4.5):	The prevalence of individual metabolic syndrome criteria among patients and controls
Fig. (4.6):	Comparison between patient's subgroups
Fig. (4.7):	Relation between chronic urticaria duration and metabolic syndrome 103

Abstract

A systemic pro-inflammatory and pro-coagulating state occurs in subjects who have both chronic urticaria and metabolic syndrome. To investigate the prevalence and clinical impact of metabolic syndrome in Egyptian patients with chronic urticaria, a case control study was performed included 160 subjects. Metabolic syndrome was assessed by the WHO criteria. Twenty one patients (26.25%) had metabolic syndrome compared to 11.25% in matched controls group (p=.015). metabolic syndrome was higher in chronic urticaria patients with long disease duration. There was a statistical significant difference as regard body mass index, serum triglyceride, high density lipoprotein, fasting blood glucose level and blood pressure. In this study metabolic syndrome was higher in chronic urticaria patients with negative autologous serum skin tests compared with those without metabolic syndrome. Also metabolic syndrome was higher in chronic urticaria with angioedema in comparison with those without angioedema.

We conclude from this study that, patients with severe and uncontrolled chronic urticaria, especially those with high body mass index should be evaluated for metabolic syndrome in order to reduce cardiovascular risk and improve chronic urticaria outcomes.

INTRODUCTION

Chronic urticaria is a common skin disorder defined by persistent or recurrent wheals and pruritus of at least 6 weeks duration. The wheals are thought to be due to activation of cutaneous mast cells, which release various of inflammatory mediators including histamine, proteases, leukotrienes and tumor necrosis factor (*Kaplan et al.*, 2009). Life time prevalence of chronic urticaria is 0.5% in general population (*Sagi et al.*, 2011).

The cardinal clinical features of urticaria that distinguish it from any other types of inflammatory eruption are the repeated occurrence of short-lived cutaneous wheals accompanied by redness and itching (*Kaplan*, 2002). It occurs most commonly in women and has a peak age of onset between 20 and 40 years (*Sussman et al.*, 2015).

Diagnosis is based on questioning and clinical examination to rule out differential diagnosis, few diagnostic tests are necessary for diagnosis and management (*Soria and Frances*, 2014).

The treatment options are primary prevention in the form of avoidance of aggravating factors, counseling, antihistamines, leukotrienes, receptor antagonists, prednisolone, sulphasalazine and immunosuppressives (*Godse*, 2009).

Chronic urticaria and metabolic syndrome share chronic low grade inflammation, involving TNF alpha, ECP and C3, they may be mutually triggered or exacerbated (*Ye et al. 2013*). Metabolic syndrome is characterized by increased levels of inflammatory marker such as IL-1, IL-6. TNF and CRP (*Devaraj et al., 2004*).

Association between metabolic syndrome and inflammatory diseases for examples: psoriasis, systemic lupus erythematosus and rheumatoid arthritis, have been reported (*Love*, 2011).

Metabolic syndrome is a complex disorder with high socioeconomic coast that is considered a worldwide epidemic, Metabolic syndromes is defined by a cluster of interconnected factors that directly increase the risk of heart disease (CHD), other forms coronary cardiovascular atherosclerotic diseases (CVD) and diabetes mellitus type 2 (DMT2) (Kassi et al., 2011). Recently the National Cholesterol Education Programs Adult Treatment Panel 111 report (ATP 111) identified six components of metabolic syndrome that related to CVD: abdominal obesity, atherogenic dyslipedimia, raised blood pressure, insulin resistance+-, glucose intolerance, proinflammatory and prothrombotic states.